Anavex Life Sciences Corp (AVXL)

[falconer66a]

Which “Precision Medicine?”

Instead of the right drug for the right patient and selecting for that match for trial inclusion, it is equally relevant to use the PM term to mean precision information from an objective biomarker confirming MoA target engagement.

I find Anavex’s use of the term “precision medicine” interesting; a bit different from the general use of the term.

Traditionally (as I understood it), “precision medicine” was the precise application of a specific therapy, indicated by very specific symptoms. Precisely, if the patient has ceratin specific symptoms and lab read-outs, a certain specific therapy was then indicated. No throwing of general therapies at generalized sets of symptoms. Therapeutic precision.

But in Anavex’s use of the term, a bit different. Genetic precision. With Anavex, in their clinical trials, a connection between specific genes or genotypes is made with the drug in trial. Not only do symptoms dictate or guide the therapy (blarcamesine), but also a patient’s particular genetics. Some patients have genes that favor blarcamesine therapy. Others, to some smaller degree, less so.

Good stuff.